

Table S2. The search strategy used for one database (Medline/PubMed) (01 Jan 2011 to 30 Nov 2020).

MEDLINE/PUBMED			
Group	MeSH (Sub-terms in MeSH)	Search Terms/Phrases	Citations
#1	<i>Mycobacterium tuberculosis</i> Tuberculosis	Drug susceptibility Anti-tuberculosis resistance Rifampicin-resistant tuberculosis Isoniazid-resistant tuberculosis Ethambutol-resistant tuberculosis Pyrazinamide-resistant tuberculosis Drug-resistant tuberculosis Drug resistance pattern Mono-resistance Hetero resistance First-line antitubercular drugs Second-line antitubercular drugs	
#2	Drug resistance Rifampicin Isoniazid Ethambutol Pyrazinamide Antitubercular agents Tuberculosis, Multidrug-resistant Extensively Drug-Resistant Tuberculosis	Molecular drug resistance diagnostics Molecular drug susceptibility testing Molecular detection of drug resistance Molecular characterization of <i>Mycobacterium tuberculosis</i> Genotypic drug sensitivity Line-probe assay <i>MTBDRplus</i> assay <i>MTBDRplus</i> VER 2.0 GenoType® <i>MTBDRplus</i> GenoType MTBDRplus V.2 Xpert MTB/RIF assay GeneXpertMTB/RIF assay GenoType® MTBDR <i>sl</i> assay	973
#3		The magnitude of gene mutations Gene mutation conferring-drug resistance Drug resistance-conferring mutations Antitubercular drug resistance determinants Antitubercular drug resistance mechanisms	
#4		Ethiopia	
#5			

(*Mycobacterium tuberculosis*[MeSH Terms]) OR Tuberculosis[MeSH Terms]) AND Drug resistance[MeSH Terms]) OR Drug susceptibility) OR Rifampicin[MeSH Terms]) OR Isoniazid[MeSH Terms]) OR Ethambutol[MeSH Terms]) OR Pyrazinamide[MeSH Terms]) OR Antitubercular agents[MeSH Terms]) OR Mono-resistance) OR Hetero-resistance) OR Anti-tuberculosis resistance) OR Rifampicin-resistant tuberculosis) OR Isoniazid-resistant tuberculosis) OR Ethambutol-resistant tuberculosis) OR Pyrazinamide-resistant tuberculosis) OR Drug-resistant tuberculosis) OR Drug resistance pattern) OR Tuberculosis, Multidrug-resistant[MeSH Terms]) OR Extensively Drug-Resistant Tuberculosis[MeSH Terms]) OR First-line antitubercular drugs) OR Second-line antitubercular drugs) AND Molecular diagnosis) OR Molecular detection) OR Molecular characterization) OR Molecular drug resistance diagnostics) OR Molecular drug susceptibility testing) OR Molecular detection of drug resistance) OR Molecular characterization of *Mycobacterium tuberculosis*) OR Genotypic drug sensitivity) OR Line-probe assay) OR *MTBDRplus* VER 2.0) OR GenoType®*MTBDRplus*) OR GenoType MTBDRplus V.2) OR Xpert MTB/RIF assay) OR GeneXpertMTB/RIF assay) OR GenoType® MTBDR*sl* assay) AND Gene mutations) OR Resistance determinants) OR Resistance mechanisms) OR Magnitude of gene mutations) OR Gene mutation conferring-drug resistance) OR Drug resistance-conferring mutations) OR Antitubercular drug resistance determinants) OR Antitubercular drug resistance mechanisms) AND Ethiopia.